6 not yet recruiting, 4 unknown, 3 recruiting, 2 completed. 10 Phase 2, 8 Phase 1, 1 Phase 3.
Follow PTCL: new trials by email Literature Review of PTCL trials Research Report on PTCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma FG-M131 - PTCL, TRBC1 ADC | Phase 1 / Phase 2 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 110 | 2026-08-30 | 2026-09-02 |
| SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) SHR2554 combined with Liposomal Mitoxantrone - PTCL, First Line Treatment | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 44 | 2026-08-01 | 2026-07-24 |
| TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma TR115, Investigator's Choice - PTCL, NK T-Cell Lymphoma | Phase 3 | Not yet recruiting | Tarapeutics Science Inc. | 180 | 2026-07-30 | 2026-06-10 |
| A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma. PTCL, T Cell Lymphoma | Not yet recruiting | Ruijin Hospital | 1000 | 2026-06-01 | 2026-06-18 | |
| Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL Zeprumetostat+Azacitadine, Zeprumetostat+Decitabine, Zeprumetostat+Chidamide - PTCL, Refractory | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 86 | 2026-03-23 | 2026-04-07 |
| SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma SHR2554 Tablets - PTCL | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 30 | 2026-02-01 | 2026-01-16 |
| Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL CD5-targeted CAR-T cells - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 30 | 2025-02-14 | 2026-05-07 |
| Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma Toripalimab, chidamide - PTCL | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 43 | 2024-04-03 | 2024-07-09 |
| A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. chidamide - PTCL | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 200 | 2023-04-01 | 2023-08-01 | |
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib | Phase 1 / Phase 2 | Unknown | Fudan University | 30 | 2022-03-01 | 2022-02-14 |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Pembrolizumab, Pralatrexate, Decitabine - PTCL, CTCL | Phase 1 | Active not recruiting | University of Virginia | 37 | 2022-02-02 | 2026-04-07 |
| A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma YY-20394 treatment - PTCL | Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 90 | 2021-04-01 | 2021-01-12 |
| Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Azacytidine, Romidepsin, Belinostat - PTCL | Phase 2 | Recruiting | University of Virginia | 50 | 2021-02-19 | 2026-01-21 |
| Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort PTX-100 - Advanced Cancer, PTCL | Phase 1 | Completed | Prescient Therapeutics, Ltd. | 25 | 2019-09-01 | 2025-09-02 |
| GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL PTCL, Gemcitabine | Unknown | Shandong Provincial Hospital | 120 | 2019-04-01 | 2019-03-21 | |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Tislelizumab - Peripheral T Cell Lymphoma, PTCL | Phase 2 | Completed | BeiGene | 77 | 2018-04-13 | 2024-10-26 |
| Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL Volasertib, Romidepsin - PTCL, CTCL | Phase 1 | Withdrawn | Anne Beaven, MD | 2016-11-01 | 2016-12-01 |
Lymphoma, T-Cell (4) · Lymphoma, Extranodal NK-T-Cell (2) · Lymphoma, T-Cell, Peripheral (2) · Immunoblastic Lymphadenopathy (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Cutaneous (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphadenopathy (1) · Lymphoma, T-Cell (1)
10-propargyl-10-deazaaminopterin (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (2) · romidepsin (2) · Azacitidine (1) · BI 6727 (1) · Cyclophosphamide (1) · Decitabine (1) · Doxorubicin (1) · Gemcitabine (1) · Vincristine (1) · belinostat (1) · parsaclisib (1) · pembrolizumab (1) · tislelizumab (1) · toripalimab (1)
Ruijin Hospital (2) · The First Affiliated Hospital with Nanjing Medical University (2) · University of Virginia (2) · Anne Beaven, MD (1) · BeiGene (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fudan University (1) · FutureGen Biopharmaceutical (Beijing) Co., Ltd (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Peking University People's Hospital (1) · Prescient Therapeutics, Ltd. (1) · Shandong Provincial Hospital (1) · Shanghai YingLi Pharmaceutical Co. Ltd. (1) · Tarapeutics Science Inc. (1)
China (8) · United States (2) · Australia (1) · Canada (1) · France (1) · Italy (1) · Taiwan (1)
Craig Portell, MD (1) · Enrica Marchi, MD, PhD (1) · Junning Cao (1) · Owen O'Connor, MD, PhD (1) · Terrence Chew, MD (1)
2017 (1)